搜索临床试验以:mFOLFOX6+贝伐珠单抗+PD-1单克隆抗体治疗组合
总计216个结果
-
Sixth Affiliated Hospital, Sun Yat-sen University招聘中
-
Sixth Affiliated Hospital, Sun Yat-sen University招聘中
-
Second Affiliated Hospital, School of Medicine,...Westlake Therapeutics招聘中
-
The First Affiliated Hospital with Nanjing Medical...招聘中
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)完全的
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.招聘中
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.招聘中
-
Beijing Friendship HospitalXuanwu Hospital, Beijing; Beijing Chao Yang Hospital; Tianjin Medical University General Hospital 和其他合作者招聘中
-
The First Affiliated Hospital with Nanjing Medical...尚未招聘
-
Cancer Institute and Hospital, Chinese Academy...Peking University Cancer Hospital & Institute; Affiliated Cancer Hospital & Institute of Guangzhou... 和其他合作者招聘中
-
LigaChem Biosciences, Inc.AntibodyChem Biosciences, Inc.招聘中
-
Peking University Cancer Hospital & Institute招聘中
-
Chinese PLA General Hospital未知
-
Peking University Cancer Hospital & Institute主动,不招人
-
Fudan UniversityShanxi Province Cancer Hospital; Inner Mongolia Cancer Hospital Affiliated To Inner Mongolia...招聘中
-
Shanghai Pulmonary Hospital, Shanghai, China尚未招聘非小细胞肺癌 | 晚期肺癌
-
Genor Biopharma Co., Ltd.Hutchison Medipharma Limited未知
-
University Hospital, Bordeaux招聘中在使用 PD1/PDL1 ICIs + VEGFR-酪氨酸激酶抑制剂治疗 12 个月时有客观反应的 mRCC 患者中只有一个不良预后因素的 IMDC 良好或中等风险的治疗暂停与治疗继续 (SPICI)转移性肾细胞癌 | 每个 IMDC 评分的良好或只有一个不良预后因素中等风险法国
-
Shandong New Time Pharmaceutical Co., LTD未知
-
Beijing 302 HospitalBeijing GD Initiative Cell Therapy Technology Co., Ltd.; Chinese Academy of Medical Sciences尚未招聘
-
Beijing 302 HospitalBeijing GD Initiative Cell Therapy Technology Co., Ltd.; Chinese Academy of Medical Sciences尚未招聘
-
The Fourth Affiliated Hospital of Zhejiang University...招聘中
-
Shanghai Junshi Bioscience Co., Ltd.未知